

ROBO Global

13:45 08 Jul 2019

Tecan is disrupting the life science and diagnostics market, says ROBO Global

Analysts at ROBO Global said they were bullish on the long-term growth outlook for Tecan Group Ltd (OTCMKTS:TCHBF), an automated lab instruments and solutions provider.

Zurich, Switzerland-based Tecan is behind the groundbreaking NuQuant technology which can reduce the time to analyze a DNA sample from several hours down to just six minutes.

"This is only one example of the company's list of innovations that have disrupted its field in the past year," wrote ROBO Global research director Jeremie Capron and senior research analyst Nina Deka in a recent report.

READ: ROBO Global captures the high-octane growth of robotics and artificial intelligence

ROBO Global created the ROBO Global Robotics & Automation Index, the world's first benchmark index to track companies that focus on robotics, automation and artificial intelligence.

As a technology leader in lab process automation, Tecan is a member of both the ROBO Global Robotics & Automation Index, and the new ROBO Global Healthcare Technology & Innovation Index.

Tecan stock was trading 13.8% up at \$261.40 on Monday.

Driving genome sequencing

"Tecan provides the chassis, nuts, and bolts that enable genomic research and drug discovery — two of the fastest growing trends in healthcare," wrote the analysts.

Specifically, Tecan provides the automation instruments and reagents (the substances used in the chemical analysis of the genes) to analyze specimens, develop new genome tests, and create new analysis procedures.

"With 30 years of experience in diagnostic research and commercialization, as well as extensive regulatory heavy lifting, Tecan helps its clients transition successful scientific discoveries into commercialized, FDA approved products," wrote the analysts.

Lonza AG (OTCMKTS:LZAGY), one of the largest manufacturers of biologics products, used Tecan's Freedom EVO platform to develop an endotoxin test, then partnered with Tecan to develop and manufacture a fully automated robotic solution for endotoxin detection.


Bullish investment case

"Tecan's strong value proposition and favorable market dynamics make for a compelling investment story," wrote the analysts.

Price: 50.79

Market Cap: \$2.83 billion

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: ROBO

Listing: NYSE

52 week	High	Low
	51.13	28.6

Sector: Medical technology & services

Website: www.roboglobal.com

Company Synopsis:

ROBO Global is an index, advisory, and research company wholly focused on helping investors capture the unique opportunities of fast-growing robotics, artificial intelligence, and healthcare technology companies around the world. In 2013, we launched the ROBO Global® Robotics and Automation Index Series.

action@proactiveinvestors.com

The analysts noted that instruments and reagents are a "highly competitive business," but the ability to help a client design, manufacture and commercialize their discovery is a "strong differentiator for Tecan."

"We believe clients will continue to seek partnerships with vendors that can not only help them develop new technologies, but market them as well," wrote the analysts.

The analysts noted that the strategy also benefits Tecan's average customer lifespan, enabling them to "land and expand" within one client, and continue to generate revenue through these partnerships during the entire life cycle of the clients' new products.

Tecan has a strong cash position to invest in mergers and acquisitions, according to ROBO Global.

"The company will continue to evaluate inorganic growth targets, ranging from small bolt-ons to larger transformational acquisition opportunities," wrote the analysts.

The ROBO Global Robotics & Automation Index ETF (NYSEARCA:ROBO) was down a little at \$39.3 in midday trade Monday.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.